Rocket Pharmaceuticals, Inc. (RCKT) Cash Flow Statement
Rocket Pharmaceuticals, Inc. (RCKT) generated -$170.3M of operating cash flow over the twelve months to 2026-06-30, spent $127000 on capital expenditure and had free cash flow of -$170.4M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RCKTRocket Pharmaceuticals, Inc.Follow RCKT — free
—
Price chart with a free account
- Market cap
- 251.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 11 days
| Line | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -17.4 | -37.3 | -26.1 | -53.8 | -64.7 | -74.6 | -121.2 | -178.1 | -194.9 | -209.7 | -190.0 | -170.3 | |
| Capital expenditure | 0.4 | 0.5 | 0.1 | 1.5 | 23.3 | 20.6 | 7.6 | 8.4 | 16.4 | 5.9 | 0.4 | -0.1 | |
| Free cash flow | -17.8 | -37.8 | -26.2 | -55.2 | -87.9 | -95.2 | -128.8 | -186.5 | -211.4 | -215.6 | -190.5 | -170.4 | |
| Share repurchases | — | — | — | 0.0 | 0.0 | 0.1 | 0.0 | — | — | — | — | — | |
| Stock-based compensation | 2.4 | 0.3 | 1.3 | 13.6 | 13.4 | 18.6 | 29.2 | 31.0 | 39.4 | 43.9 | 37.1 | — |
USD millions · SEC XBRL
Rocket Pharmaceuticals, Inc. — questions
- What is Rocket Pharmaceuticals, Inc.'s operating cash flow?
- -$170.3M over the twelve months to 2026-06-30.
- How much does Rocket Pharmaceuticals, Inc. spend on capital expenditure?
- $127000 over the twelve months to 2026-06-30.
- What is Rocket Pharmaceuticals, Inc.'s free cash flow?
- -$170.4M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Rocket Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.